CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma by Pannem, Rajeswara Rao et al.
© The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
Carcinogenesis vol.35 no.2 pp.461–468, 2014
doi:10.1093/carcin/bgt335
Advance Access publication October 8, 2013
CYLD controls c-MYC expression through the JNK-dependent signaling pathway in 
hepatocellular carcinoma
Rajeswara Rao Pannem, Christoph Dorn1, 
Kristofer Ahlqvist, Anja K.Bosserhoff2, 
Claus Hellerbrand1 and Ramin Massoumi* 
Department of Laboratory Medicine, Skåne University Hospital, Lund 
University, Malmö SE-20502, Sweden, 1Department of Internal Medicine I, 
University Hospital of Regensburg, Regensburg 93053, Germany and 2Institute 
of Pathology, University of Regensburg, Regensburg 93053, Germany
*To whom correspondence should be addressed. Tel: +46 40 331228;  
Fax: +46 40 337063;  
Email: Ramin.Massoumi@med.lu.se
Posttranslational modification of different proteins via direct ubiq-
uitin attachment is vital for mediating various cellular processes. 
Cylindromatosis (CYLD), a deubiquitination enzyme, is able to 
cleave the polyubiquitin chains from the substrate and to regu-
late different signaling pathways. Loss, or reduced expression, 
of CYLD is observed in different types of human cancer, such as 
hepatocellular carcinoma (HCC). However, the molecular mecha-
nism by which CYLD affects cancerogenesis has to date not been 
unveiled. The aim of the present study was to examine how CYLD 
regulates cellular functions and signaling pathways during hepa-
tocancerogenesis. We found that mice lacking CYLD were highly 
susceptible to chemically induced liver cancer. The mechanism 
behind proved to be an elevated proliferation rate of hepatocytes, 
owing to sustained c-Jun N-terminal kinase 1 (JNK1)-mediated 
signaling via ubiquitination of TNF receptor-associated factor 2 
and expression of c-MYC. Overexpression of wild-type CYLD in 
HCC cell lines prevented cell proliferation, without affecting apop-
tosis, adhesion and migration. A combined immunohistochemical 
and tissue microarray analysis of 81 human HCC tissues revealed 
that CYLD expression is negatively correlated with expression of 
proliferation markers Ki-67 and c-MYC. To conclude, we found 
that downregulation of CYLD induces tumor cell proliferation, 
consequently contributing to the aggressive growth of HCC. Our 
findings suggest that CYLD holds potential to serve as a marker 
for HCC progression, and its link to c-MYC via JNK1 may provide 
the foundation for new therapeutic strategies for HCC patients.
Introduction
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-
related death worldwide. HCC typically arises in patients with hepatitis 
(also viral) or cirrhosis in combination with accumulating genetic alter-
ations, including mutation of tumor suppressor and/or proto-oncogenes 
(1–3). Since the prognosis remains poor for patients diagnosed at an 
advanced stage, there is a need for improved diagnosis and treatment.
Ubiquitination and deubiquitination are established mechanisms 
for cellular homeostasis; dysregulation occurring in this system alters 
the function of the cell. Generally, polyubiquitination of any substrate 
through Lys-48-linkage, targets the protein for proteasome-mediated 
degradation, whereas Lys-63-linked ubiquitin chains add new func-
tional properties to the modified protein (4,5). Ubiquitination is revers-
ible by action and activation of deubiquitination enzymes (6,7). We, 
and others, have demonstrated that the cylindromatosis (CYLD) gene 
product, which is a deubiquitination enzyme, functions as a tumor sup-
pressor in different types of cancer, such as melanoma, basal cell carci-
noma and colon and lung cancer (8–12). By removing ubiquitin chains 
from the different substrates, including the TNF receptor-associated 
factor 2/6 (TRAF2/6), the transforming growth factor β-activated 
kinase 1 and the B-cell lymphoma 3-encoded protein (Bcl-3), CYLD 
interferes with signaling pathways, such as nuclear factor kappa B 
(NF-κB) and c-Jun N-terminal kinase (JNK), thus regulating cell pro-
liferation and cell survival (13–15). The involvement of CYLD is not 
restricted to removal of Lys-63 polyubiquitin chains from different 
substrates but has been shown to interfere with other signaling path-
ways as well, independent of its deubiquitin activity (16).
We have shown previously that the CYLD messenger RNA 
expression in HCC, in situ as well as in cell lines, is downregulated 
in comparison with non-neoplastic tissue samples or cells (17). 
Recent studies demonstrated that CYLD is an important regulator of 
hepatocyte homeostasis, by protecting cells from apoptosis, which 
further prevents the initiation phase of HCC development (18,19). 
Furthermore, overexpression of CYLD in HCC cell lines decreases 
NF-κB activation, augmenting the antitumorous effect of TRAIL (18), 
caused by a direct binding of CYLD to IkB kinase gamma subunit 
in TRAIL-mediated NF-κB signaling (20). Notably, CYLD expres-
sion alone in HCC cell lines had minor antitumor activity, whereas 
a combinational expression of CYLD and TRAIL initiated apoptosis 
in those cells (20). In another recent study, downregulation of CYLD 
resulted in an increased resistance to treatment with anticancer drugs, 
suggesting that CYLD expression plays a major role in overcoming 
therapy resistance in HCC (21,22). Notwithstanding these significant 
observations, the molecular mechanism by which CYLD affects hepa-
tocancerogenesis has yet not been unveiled.
In the present study, we revealed that CYLD critically affects pro-
liferation in HCC cells in vitro, and in an experimental HCC model 
in mice. We observed an inverse correlation between loss of CYLD 
expression and cell proliferation in human HCC tissues, and we found 
that CYLD, via JNK1, inhibits the c-MYC expression in HCC cells.
Materials and methods
Cells and cell culture
Primary murine hepatocytes were isolated, using a modified two-step ethyl-
eneglycol-bis(aminoethylether)-tetraacetic acid/collagenase perfusion proce-
dure, and cultured as described previously (23). The HCC cell lines HepG2 
(ATCC HB-8065), PLC (ATCC CRL-8024), Huh7 (ATCC PTA-4583) and 
Hep3B (ATCC HB-8064) were cultured as described previously (24).
Animals, experimental in vivo models and ethical consideration
Generation of CYLD knockout (KO or CYLD−/−) mice has been described 
previously (10). All mice were maintained in specific pathogen-free hous-
ing at the Clinical Research Centre in Malmö, and the animal experiments 
were performed according to national and international guidelines of the 
European Union. To induce hepatocarcinogenesis, male mice were injected 
intraperitoneally with 25 mg/kg of diethylnitrosamine (DEN) (Sigma–Aldrich, 
Stockholm, Sweden) at the age of 15 days and were subsequently observed for 
development of tumors. The cohort was killed at 12 months of age, in accord-
ance with the protocol. For short-term studies of acute liver injury, 15 days old 
mice were injected intraperitoneally with DEN. The mice were subsequently 
killed at the indicated time points (3, 6, 12, 24, 48, 72 h after injection). JNK 
inhibition was accomplished by injection (intraperitoneally) of 30 μg/g body 
weight of the JNK-specific inhibitor SP600125 (Sigma–Aldrich) 1 h prior to 
DEN injection. Control mice received only the solvent dimethyl sulfoxide.
HCC tissue microarrays and immunohistochemical analyses
Tissue microarrays (TMA) were constructed (as described in refs 24,25), 
consisting of 85 formalin-fixed, paraffin-embedded human HCC tissues, and 
corresponding non-neoplastic liver tissue of the same patient (in 80 cases). 
Clinicopathological patient characteristics are summarized in Supplementary 
Table 1, available at Carcinogenesis Online. Immunohistochemical stain-
ing of 5 μm sections of the TMA blocks was performed, using a CYLD 
antibody (rabbit polyclonal, 1:100, #SAB4200060 from Sigma–Aldrich) 
or a c-MYC antibody (rabbit polyclonal, 1:50, from Abcam), utilizing an 
Abbreviations: Bcl-3, B-cell lymphoma 3-encoded protein; CYLD, cylin-
dromatosis; DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; JNK1, 
c-Jun N-terminal kinase 1; NF-κB, nuclear factor kappa B; TMA, tissue 
microarray; TRAF, TNF receptor-associated factor 2.
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indirect immunoperoxidase protocol in accordance with the LSAB2-kit 
(DAKO, Hamburg, Germany). The primary antibody was omitted for nega-
tive control; the immunoglobulin G isotype control antibodies did not produce 
any detectable staining. For the TMA evaluation, any detectable cytoplasmic 
staining was defined as the tissue sample being CYLD positive, and detectable 
nuclear staining was defined as the tissue sample being c-MYC positive. In 
contrast, samples designated as CYLD negative or c-MYC negative did not 
reveal any immunohistochemical staining. MiB-1 was analyzed by applying an 
anti-Ki-67 antibody (rabbit monoclonal, clone MiB-1, 1:10, final concentration 
of 5 g/ml; DAKO). Antibody binding was visualized by using an AEC solution 
(LSAB2-Kit; DAKO). Finally, the tissues were counterstained with hemalaun. 
Furthermore, immunohistochemical analyses of murine liver sections were per-
formed, using rabbit polyclonal CYLD (1:600), rabbit polyclonal Bcl-3 (C-14), 
mouse monoclonal phospho-JNK1 (G-7) and polyclonal p65 (F-6) antibodies 
from Santa Cruz Biotechnology.
RNA isolation and real-time quantitative PCR
Total RNA was isolated from liver tissue and cells, using a nucleospin RNA II kit 
(Macherey-Nagel) in accordance with the manufacturer’s instructions. Reverse 
transcription of total RNA (1.5 μg) into first strand complementary DNA was per-
formed by means of an AffinityScript™ QPCR cDNA synthesis kit (Stratagene) 
for quantitative PCR, using oligo (deoxythymidine) primers. Quantitative PCR 
was performed using SYBR® Green QPCR master mix (Stratagene), and mes-
senger RNA expression analyses were performed using QuantiTect Primer 
Assays, in accordance with the manufacturer’s instructions (Qiagen, Hilden, 
Germany). Genes and primer sequences were: hCYLD, forward: 5′-TGC CTT 
CCA ACT CTC GTC TTG-3′ and reverse: 5′-AAT CCG CTC TTC CCA GTA 
GG-3′; hBeta actin, forward: 5′-CTA CGT CGC CCT GGA CTT CGA GC-3′ 
and reverse: 5′-GAT GGA GCC GCC GAT CCA CAC GG-3′; mCYLD, for-
ward: 5′-ACA ACA TGG ATG CCA GGT TG-3′ and  reverse: 5′-CCG CTA 
ATA AAG GTC CTC TG-3′; mGAPDH, forward: 5′-TCG TGG ATC TGA CGT 
GCC GCC-3′ and reverse: 5′-CAC CAC CCT GTT GCT GTA GCC-3′.
Statistical analyses
Statistical analyses were performed, using SPSS 15.0 (SPSS, Chicago, IL) 
and GraphPad Prism Software (GraphPad Software). Results are expressed as 
means ± SD or as percentages. Groups were compared by means of a paired 
t-test. Fisher’s exact test was used to study the statistical association between 
clinicopathological and immunohistochemical variables. Significance was 
accepted at the level P < 0.05 (*). Further details of our methods can be found 
in supplementary methods.
Results
CYLD−/− mice are highly sensitive to liver tumor development
Mice lacking the CYLD gene have no obvious phenotype and have 
a normal life span (10). Immunohistochemical analyses showed that 
CYLD was ubiquitously expressed in human and murine liver tissues 
(Supplementary Figure 1, available at Carcinogenesis Online). Up to 
the age of 1 year, the liver of CYLD-deficient mice displayed regular 
cell morphology and cellular integrity, and they did not develop spon-
taneous liver tumors.
After a latency period of 12 months, we observed HCC development in 
both wild-type and CYLD knockout mice that at the age of 15 days had 
been exposed to the chemical carcinogen DEN (Figure 1A). Liver weight, 
tumor numbers, tumor size and maximal tumor size were significantly 
increased in CYLD−/− mice compared with control mice (Figure 1B–E). 
Furthermore, trabecular sinusoidal structures, a pathological alteration of 
liver plates frequently occurring in human HCC, which is related to the 
initiation stage of metastasis and invasion (26), were more prominent in 
tumor tissue of CYLD−/− mice than in control mice (Figure 1F).
CYLD-deficient tumors exhibit increased cell proliferation
The examination of the mechanism behind cell proliferation and 
cell apoptosis in HCC revealed that Ki-67 (Figure  2A) and cyclin 
D1 expressions (Figure 2B) were significantly increased in CYLD−/− 
tumors, as was the percentage of proliferating cell nuclear antigen-
positive cells in the surrounding non-tumoral liver tissue (Figure 2C). 
Fig. 1. Loss of CYLD potentiates DEN-induced liver tumor development in mice. (A) Mice were injected intraperitoneally with 25 mg/kg of DEN at 15 days 
of age, and livers of wild-type (n = 16) and CYLD-deficient mice [knockout (KO)] (n = 16) were isolated after a latency period of 12 months. (B) Mean total 
liver weight of wild-type (n = 16) and CYLD-deficient mice (n = 16). Results are means ± SD; *P < 0.05 denotes significant differences between the groups. 
(C) Number of tumors in wild-type (n = 16) and CYLD-deficient mice (n = 16). Results are means ± SD; *P < 0.05 denotes significant differences between 
the groups. (D) Size of the tumors (≥5 mm) in wild-type (n = 16) and CYLD-deficient mice (n = 16) after treatment in situ with DEN. Results are means ± SD; 
*P < 0.05 denotes significant differences between the groups. (E) Maximal tumor size in 12 months old wild-type (n = 16) and CYLD-deficient mice (n = 16). 
Results are means ± SD; *P < 0.05 denotes significant differences between the groups. (F) Hematoxylin and eosin staining of tumors isolated from wild-type 
and CYLD-deficient mice. Non-tumor (NT) and tumor (T) tissues of liver sections from wild-type mice are indicated in ×10 and ×40 magnifications. CYLD KO 
tumor tissue displays trabecular sinusoidal structures, which is absent in control tumor tissue (×40).
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In addition, this effect was tissue specific, since the levels of cyclin 
D1 did not differ in other non-tumoral tissues, such as brain and lung, 
between the experimental groups (Supplementary Figure 2, available 
at Carcinogenesis Online). Furthermore, we did not detect any differ-
ences in the number of apoptotic cells between tumors isolated from 
wild-type and tumors from CYLD−/− mice (Figure 2D). These results 
were confirmed by using TMA technology (24,25) on a series of 81 
HCC patients (Supplementary Table  1, available at Carcinogenesis 
Online), which revealed the CYLD expression to be negatively cor-
related with a high MiB-1 index (Supplementary Table 2, available 
at Carcinogenesis Online, Figure 2E). CYLD protein expression was 
found in all (n = 75) non-cancerous tissue samples; in 43.2% (35/81) 
of the HCC, no CYLD immunosignal was detectable. Representative 
immunohistochemical stainings of CYLD-positive and CYLD-
negative tumor tissues are presented in Supplementary Figure 3, avail-
able at Carcinogenesis Online.
CYLD-deficient tumors exhibit increased JNK1 activation
The western blot analysis of liver tumors isolated from CYLD−/− and 
CYLD+/+ mice revealed that tumors isolated from CYLD-deficient 
animals exhibited high levels of phospho-JNK1 (Figure  3A) under 
non-induced conditions, without affecting the total level of JNK1 
(Figure  3B). Furthermore, tumors isolated from CYLD-deficient 
animals showed high levels of c-MYC and ubiquitinated TRAF2, 
compared with wild-type tumors (Figure 3C and D). No difference in 
the activation of extracellular signal-regulated kinase or Akt/protein 
kinase B was observed between wild-type tumors and CYLD-
deficient tumors (Figure 3E).
Loss of CYLD promotes TRAF2-mediated JNK1 activation and 
proliferation in the acute phase of liver injury
In exploring the foundation for the increased susceptibility of CYLD−/− 
mice to chemically induced carcinogenesis, we observed that after 72 
h, DEN treatment of liver tissue had significantly increased the num-
ber of proliferating cells in CYLD−/− mice (Figure  4A). Moreover, 
72 h after treatment with DEN, the cyclin D1 expression was ele-
vated in liver tissue isolated from CYLD−/− but not in CYLD+/+ mice 
(Supplementary Figure 4, available at Carcinogenesis Online). The 
levels of p53 (Supplementary Figure 5, available at Carcinogenesis 
Online) or serum levels of aspartate aminotransferase (Supplementary 
Figure 6, available at Carcinogenesis Online) did not differ signifi-
cantly between the experimental groups. DEN treatment (72 h) of 
Fig. 2. Absence of CYLD is associated with increased cell proliferation in HCC. (A) Analysis of Ki-67-positive cells in tumors of wild-type and CYLD-deficient 
mice treated with DEN, 15 days after treatment and after a latency period of 12 months. Results are means ± SD; *P < 0.05 denotes significant differences 
between the groups. (B) The levels of cyclin D1 in three different tumors from 12 months old wild-type and CYLD-deficient mice, 1 year after DEN treatment. 
(C) Analysis of proliferating cell nuclear antigen (PCNA)-positive cells in non-tumorous liver tissue of 12 months old wild-type and CYLD-deficient mice, 
1 year after DEN treatment. Results are means ± SD; *P < 0.05 denotes significant differences between the groups. (D) A terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) assay analysis of apoptotic cells in liver tumors of wild-type and CYLD-deficient mice, 15 days after treatment with 
DEN, and after a latency period of 12 months. (E) Proliferation rate (analyzed by immunohistochemical staining, using anti-Ki-67 antibodies) in HCC tissues 
showing positive or negative immunoreactivity to CYLD, applying TMA technology.
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liver sections isolated from CYLD−/− mice significantly increased 
the number of cells displaying nuclear staining of phospho-JNK1, 
but not of Bcl-3 or p65, in contrast to CYLD+/+ mice (Figure  4B 
and Supplementary Figure 7, available at Carcinogenesis Online). 
Furthermore, DEN treatment in vitro resulted in an increase in JNK1 
activation in hepatic tissue from CYLD−/− mice (Figure 4C) as well 
as in primary hepatocytes of CYLD−/− mice (Figure  4D), as com-
pared with CYLD+/+ hepatocytes. DEN exposure promoted upregula-
tion of TRAF2 ubiquitination in CYLD−/− but not in CYLD+/+ liver 
tissue (Figure  4E), and did not change the total level of TRAF2 
(Supplementary Figure 8, available at Carcinogenesis Online). A sig-
nificant increase in the levels of c-MYC (another downstream target 
protein responsible for JNK1-mediated proliferation of HCC) upon 
48 h of DEN treatment was observed in CYLD−/− but not in CYLD+/+ 
mice (Figure 4F). However, under non-induced condition, the levels 
of c-MYC was low and did not differ between CYLD+/+ and CYLD−/− 
mice (Figure 4G).
CYLD expression in HCC cells reduces JNK1-mediated signaling 
and cell proliferation
The assessment of four different human HCC cell lines, analyz-
ing whether the expression of CYLD is important for inhibition of 
JNK1-mediated cancer cell proliferation, revealed a reduced CYLD 
expression in all HCC cell lines in comparison with primary hepato-
cytes (Figure 5A; ref. 17). The expression of CYLD was inversely 
correlated with the proliferation capacity of the different HCC 
cell lines (Figure  5B). Overexpression of CYLD in HepG2, PLC 
and Huh7 cells reduced their proliferation rate (Figure  5C and 
Supplementary Figure 9A, available at Carcinogenesis Online). 
However, no differences were observed in the number of apoptotic 
cells, cell adhesion or migration in cells transfected with full-length 
CYLD in comparison with MOCK-transfected cells (Supplementary 
Figure 10, available at Carcinogenesis Online). Furthermore, over-
expression of full-length CYLD reduced the levels of c-MYC, cyclin 
D1 and JNK1 phosphorylation (Figure 5D and Supplementary Figure 
9B, available at Carcinogenesis Online), and also reduced TRAF2 
ubiquitination (Figure  5E and Supplementary Figure 9C, avail-
able at Carcinogenesis Online) and transcriptional activity of AP-1 
(Figure 5F and Supplementary Figure 9D, available at Carcinogenesis 
Online). Since downregulation of c-MYC did not influence the activ-
ity of JNK, this suggests that in HepG2 cells JNK activation oper-
ates upstream of c-MYC expression (Figure  6A). As expected, 
downregulation of c-MYC in HepG2, PLC and Huh7 cells reduced 
proliferation (Figure  6B and Supplementary Figure 11A and B, 
available at Carcinogenesis Online) but not the number of apoptotic 
cells (Figure 6C), and overexpression of CYLD reduced the c-MYC 
Fig. 3. Elevated activation of JNK1 in tumors isolated from CYLD-deficient mice. (A) The levels of phospho-JNK1 (p-JNK1) and total JNK1 in three different 
tumors from 12 months old DEN-treated wild-type and CYLD-deficient mice. (B) The levels of total JNK1 and actin in livers of adult (12 months) wild-type 
(n = 3) and CYLD-deficient mice (n = 3). (C) TRAF2 ubiquitination in two different tumors, isolated from 12 months old DEN-treated wild-type and CYLD-
deficient mice. (D) The levels of c-MYC and actin in three different tumors from 12 months old DEN-treated wild-type and CYLD-deficient mice. (E) The levels 
of phospho-extracellular signal-regulated kinase (p-ERK), total ERK, phospho-Akt (p-Akt) and actin in three different tumors from 12 months old DEN-treated 
wild-type and CYLD-deficient mice.
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promoter activity in HCC cell lines (Figure 6D and Supplementary 
Figure 11C, available at Carcinogenesis Online). Furthermore, the 
c-MYC expression was significantly increased in tumors of CYLD−/− 
mice but not in tumors of wild-type mice (Figure 6E). Next, we ana-
lyzed whether inhibition of JNK is able to ameliorate proliferation 
and c-MYC expression in CYLD-deficient mice. Intraperitoneal 
injection of JNK-specific inhibitor SP600125 prior to DEN treatment 
significantly reduced cyclin D1 and c-MYC expression (Figure 6F), 
as well as the number of proliferating (Ki-67-positive) hepatocytes in 
CYLD-deficient mice (Figure 6G and H).
The results of the analyses of c-MYC protein expression in human 
HCC tissues (using TMA) are illustrated in Supplementary Table 3, 
available at Carcinogenesis Online. We observed nuclear c-MYC 
staining in 21 of 81 informative cases, whereas no c-MYC immunosig-
nal was detectable in the remaining 57 HCC tissues. Representative 
immunohistochemical staining of c-MYC-positive and c-MYC-nega-
tive HCC tissues is depicted in Supplementary Figure 12, available at 
Carcinogenesis Online. Expression of c-MYC was significantly asso-
ciated with a higher MiB-1 labeling index (Supplementary Table 3, 
available at Carcinogenesis Online). Furthermore, we observed a 
negative correlation between CYLD and c-MYC expression in human 
HCC (Supplementary Table 2, available at Carcinogenesis Online). 
These findings demonstrate that in conjunction, a reduced CYLD and 
a high c-MYC expression have a significant impact on the prolifera-
tion rate in human HCC cells and tissues.
Discussion
Hepatocarcinogenesis is a multistep process, characterized by accu-
mulation and interplay of genetic alterations. In particular, mutations 
in proto-oncogenes and loss of tumor suppressor genes play a critical 
role in development and progression of human HCC (1–3). Cellular 
injury and release of growth factors and cytokines induce prolifera-
tion of hepatocytes, and a high hepatocyte proliferation rate is gener-
ally acknowledged as a predictive factor of human HCC development 
(27). Previous studies detected downregulation, or loss, of the CYLD 
gene in human HCC cell lines and tissues (17,28), and reduced copy 
numbers of the CYLD gene were observed in >30% of hepatitis C 
Fig. 4. JNK1 signaling mediates TRAF2 ubiquitination and cell proliferation in CYLD-deficient cells and tissues. (A) The presence of bromodeoxyuridine-positive 
cells in the liver of 15 days old wild-type (n = 3) and CYLD-deficient mice (n = 3) 24 and 72 h post-DEN treatment. Results are means ± SD of three separate 
experiments; *P < 0.05 denotes significant differences between the groups. (B) Immunohistochemical analysis of phospho-JNK1 (p-JNK1) in livers of 15 days 
old wild-type (n = 3) and CYLD-deficient mice (n = 3) 72 h after DEN treatment. (C) The levels of p-JNK1 and total JNK1 in livers of 15 days old wild-type and 
CYLD-deficient mice after DEN treatment (3, 6, 12, 24 and 48 h posttreatment). Representative blots of at least three separate experiments. Numbers above p-JNK1 
blots represent a densitometric analysis of the protein bands; data were normalized to actin and are expressed as fold change relative to total JNK1.  
(D) The levels of p-JNK1 and total JNK1 in freshly isolated primary wild-type and CYLD-deficient hepatocytes after treatment with DEN for 24 h. Representative 
blots of at least two separate experiments. Numbers above p-JNK1 blot represent a densitometric analysis of the protein bands; data were normalized to actin and 
are expressed as fold change relative to total JNK1. (E) The levels of TRAF2 ubiquitination in livers of DEN-treated wild-type and CYLD-deficient mice (24 and 
48 h posttreatment). Representative blots of at least two separate experiments. (F) The levels of c-MYC in livers from three different wild-type and two different 
CYLD-deficient mice after treatment with DEN for 48 h. (G) The levels of c-MYC in livers from non-treated wild-type and CYLD-deficient mice.
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virus-associated HCCs (29). The present study hypothesized that 
CYLD may act as a tumor suppressor in HCC, and liver cancer for-
mation in mice lacking the CYLD gene was thus investigated.
CYLD-deficient animals, not developing spontaneous liver tumors 
up to the age of 1 year, were (as was shown in our experimental model) 
sensitive to induced HCC formation. Exposure of CYLD-deficient 
infant male mice to the chemical carcinogen DEN resulted in a sig-
nificantly higher tumor incidence, and they developed significantly 
larger and more abundant tumors than their littermate controls. The 
increased tumor development in these mice was due to a dramatically 
elevated proliferation rate of the tumor cells, but tumor cell survival 
was not significantly altered. It has previously been suggested that 
CYLD deletion interferes with migration and invasion of tumor cells 
(30,31). In our model, we did not detect any invading or metastatic 
HCC cells in lymph nodes or in any other organs of CYLD-deficient 
animals (data not shown). Furthermore, overexpression of CYLD in 
HCC cells impaired proliferation but did not cause any significant 
changes in cell survival, adhesion or migration. Importantly, also in 
human HCC tissue, the CYLD expression showed an inverse correla-
tion with mitotic activity but no correlation with tumor staging.
CYLD has previously been shown to interfere with different signal-
ing pathways, including classical NF-κB, Bcl-3 and JNK, implicated 
in cell survival and proliferation (13–15). Although we did not observe 
any differences in NF-κB and Bcl-3 signaling, HCC isolated from 
CYLD-deficient mice contained elevated levels of activated JNK1. 
Already during the initiation phase of the DEN treatment or during 
the early phase of tumor development, a significant difference between 
CYLD−/− and CYLD+/+ hepatocytes in terms of JNK1 activation was 
Fig. 5. Overexpression of CYLD in HCC cell lines prevents aberrant cell proliferation. (A) Expression levels of CYLD at the messenger RNA (mRNA) levels 
in primary hepatocytes from two donors, and the four HCC cell lines HepG2, Huh7, Hep3B and PLC. (B) Correlation between CYLD mRNA levels and 
proliferation rates of HCC cell lines (HepG2, Huh7 and PLC) after 72 h, using the ‘Viability and cell count’ protocol (NucleoCounter NC-3000; Chemometec). 
(C) Proliferation rate of HepG2 cells transiently transfected with control plasmid (Ctrl) or full-length CYLD expression plasmid, 72 h posttransfection, using the 
‘Viability and cell count’ protocol (NucleoCounter NC-3000; Chemometec). Results are means ± SD of four separate experiments; *P < 0.05 denotes significant 
differences between the groups. (D) The expression levels of phospho-JNK1 (p-JNK1), c-MYC, HA-CYLD and cyclin D1 in HepG2 cells transfected with 
MOCK (Ctrl), or with human influenza hemagglutinin (HA)-tagged, full-length CYLD for 48 h. (E) TRAF2 ubiquitination in HepG2 cells, transiently transfected 
for 48 h with FLAG-TRAF2 and control plasmid (Ctrl), or with FLAG-TRAF2 and full-length CYLD. (F) AP-1 luciferase promoter activity in HepG2 cells 
transfected for 48 h with pGL2-AP1 and control plasmid (Ctrl), or with pGL2-AP1 and with full-length CYLD. The dual-luciferase reporter assay system was 
employed for the analysis (Promega). The promoter-driven Renilla control vector was used as an internal control to normalize the values of the experimental 
reporter gene. Results are means ± SD of four separate experiments; *P < 0.05 denotes significant differences between the groups.
466
Downloaded from https://academic.oup.com/carcin/article-abstract/35/2/461/2462788
by Universitatsbibliothek Regensburg user
on 03 April 2018
CYLD reduces c-MYC in HCC
evident. The immediate JNK1 signaling may affect cell prolifera-
tion and/or cell survival, associated with HCC (32–37). A  previous 
study by Nikolaou et al. (18) reported that the expression of a deu-
biquitinase-deficient form of CYLD caused apoptosis of hepatocytes 
due to the activation of JNK. In contrast to their finding, a complete 
deletion of CYLD did (in the present study) not affect the number of 
apoptotic cells or the JNK1 activation under non-inducing conditions. 
Furthermore, we found that in mice, upon exposure to DEN, elevated 
JNK1 activation in CYLD−/− liver tissues promoted cell proliferation 
but did not alter the rate of cell survival. These phenotypic differences 
may be explained by CYLD deletion (of exon 9) being complete in our 
study, whereas only partial in the study by Nikolaou et al. (18).
JNK1-deficient mice have been described to be less susceptible to 
DEN-induced liver cancer, and human HCC sections have been shown 
to display an elevated activation of JNK1 in cancer cells, in comparison 
with adjacent non-cancerous tissue (38–40). In cancer cells, a sustained 
JNK1 phosphorylation through ubiquitination of TRAF2 may lead to 
transcriptional activation of target genes, and the AP-1 transcription 
factor is an important downstream signal of JNK activation (41).
Our study supports these findings; we observed that loss of CYLD 
did not result in deubiquitination of TRAF2. This facilitated activation 
of JNK1 and promoter activation of AP-1, leading to transcription of 
genes important for cell proliferation, such as cyclin D1 and c-MYC. 
These results suggest that inactivation of the JNK1-signaling path-
way by CYLD reduces the c-MYC and cyclin D1 expressions, thus 
preventing aberrant proliferation of hepatocytes and tumor cells, 
which agrees with previous observations that JNK deletion results in 
a reduced expression of cyclin D1 in hepatocyte and HCC cell pro-
liferation (39,42,43), and that cyclin D1 is an AP-1 target gene (44).
It has been shown earlier that JNK activation by external stimuli 
or growth factors leads to phosphorylation of AP-1 transcription fac-
tors, including c-Jun and Jun-D. The JNK docking motif of c-Jun are 
serine 63 and 73 leading to the activity of the kinase (45). In addition, 
a recent study demonstrated that JNK-dependent phosphorylation 
of c-Jun, releases c-Jun from the constitutively repressed complex 
containing histone deacetylases (46). JNK1 has also been shown to 
directly stabilize c-MYC protein levels by phosphorylation (47).
Our study actually uncovers a link between CYLD and c-MYC, via 
JNK1, offering a mechanistic insight into the role of CYLD deficiency 
in tumor initiation and progression. A small molecule c-MYC inhibi-
tor has recently been shown to inhibit HCC cell growth and to sen-
sitize these cells to chemotherapeutic agents (48). The identification 
Fig. 6. Inverse correlation between CYLD and c-MYC protein expression in human liver tumor tissues. (A) Expression levels of c-MYC protein in HepG2 after 
transient transfection for 48 h with control (Ctrl) or c-MYC small interfering RNA (siRNA) oligos. (B) Evaluation of proliferation rate in HepG2 cells 48 h after 
being transiently transfected with control (Ctrl) or c-MYC siRNA oligos, using the ‘Viability and cell count’ protocol (NucleoCounter NC-3000; Chemometec). 
Results are means ± SD of three separate experiments; *P < 0.05 denotes significant differences between the groups. (C) DNA fragmentation assay results 
(NucleoCounter NC-3000 system) in HepG2 cells transiently transfected with control (Ctrl) or c-MYC siRNA oligos, 72 h posttransfection. Results are means 
± SD of four separate experiments; *P < 0.05 denotes significant differences between the groups. (D) c-MYC luciferase promoter activity in HepG2 cells 
transfected for 48 h with c-MYC promoter luciferase and control plasmid (Ctrl), or with c-MYC promoter luciferase and full-length CYLD. The dual-luciferase 
reporter assay system was applied for the analysis (Promega). The promoter-driven Renilla control vector was used as an internal control to normalize the values 
of the experimental reporter gene. Results are means ± SD of three separate experiments; *P < 0.05 denotes significant differences between the groups.  
(E) Immunohistochemical analysis of c-MYC expression in 12 months old DEN-treated wild-type and CYLD-deficient animals. (F) The expression levels of 
cyclin D1 and c-MYC in livers from knockout (KO) mice treated with DEN (n = 2), or with the JNK-specific inhibitor (JNKi) SP600125 prior to DEN treatment 
(n = 2). (G) Immunohistochemical staining for Ki-67 and c-MYC in livers of KO mice treated with DEN, or with the JNKi SP600125 prior to DEN treatment. 
(H) Analysis of Ki-67-positive cells in livers of KO mice treated with DEN, or with the JNKi SP600125 prior to DEN treatment. Results are means ± SD; 
*P < 0.05 denotes significant differences between the groups.
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of the link between CYLD and c-MYC may be the foundation for 
exploring new therapeutic avenues for treating HCC, and potentially 
other kinds of tumors as well.
Supplementary material
Supplementary Tables 1–3 and Figures 1–12 can be found at http://
carcin.oxfordjournals.org/
Funding
Swedish Society for Medical Research; the Swedish Cancer 
Foundation; the Swedish Medical Research Council; the Royal 
Physiographic Society in Lund; U-MAS Research Foundations; the 
European Research Council, under the European Union’s Seventh 
Framework Programme for Research and Technology Development 
(260460 to R.M.); German Research Foundation (Deutche 
Forchungsgemeinschaft); the Medical Faculty of the University of 
Regensburg (ReForM-program), awarded to A.K.B. and C.H.
Acknowledgement
We thank Elise Nilsson and Rudolf Jung for excellent technical assistance.
Conflict of Interest Statement: None declared.
References
 1. El-Serag,H.B. et al. (2008) Diagnosis and treatment of hepatocellular car-
cinoma. Gastroenterology, 134, 1752–1763.
 2. Farazi,P.A. et  al. (2006) Hepatocellular carcinoma pathogenesis: from 
genes to environment. Nat. Rev. Cancer, 6, 674–687.
 3. Whittaker,S. et al. (2010) The role of signaling pathways in the development 
and treatment of hepatocellular carcinoma. Oncogene, 29, 4989–5005.
 4. Pickart,C.M. (2001) Mechanisms underlying ubiquitination. Annu. Rev. 
Biochem., 70, 503–533.
 5. Weissman,A.M. (2001) Themes and variations on ubiquitylation. Nat. Rev. 
Mol. Cell Biol., 2, 169–178.
 6. Nijman,S.M. et al. (2005) A genomic and functional inventory of deubiq-
uitinating enzymes. Cell, 123, 773–786.
 7. Harhaj,E.W. et al. (2011) Deubiquitinases in the regulation of NF-κB sign-
aling. Cell Res., 21, 22–39.
 8. Deng,L.L. et al. (2012) Over-expressing CYLD augments antitumor activ-
ity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer 
cells. Neoplasma, 59, 18–29.
 9. Massoumi,R. (2011) CYLD: a deubiquitination enzyme with multiple roles 
in cancer. Future Oncol., 7, 285–297.
 10. Massoumi,R. et al. (2006) Cyld inhibits tumor cell proliferation by block-
ing Bcl-3-dependent NF-kappaB signaling. Cell, 125, 665–677.
 11. Massoumi,R. et al. (2009) Down-regulation of CYLD expression by Snail 
promotes tumor progression in malignant melanoma. J. Exp. Med., 206, 
221–232.
 12. Zhang,J. et  al. (2006) Impaired regulation of NF-kappaB and increased 
susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. 
J. Clin. Invest., 116, 3042–3049.
 13. Massoumi,R. (2010) Ubiquitin chain cleavage: CYLD at work. Trends 
Biochem. Sci., 35, 392–399.
 14. Sun,S.C. (2008) Deubiquitylation and regulation of the immune response. 
Nat. Rev. Immunol., 8, 501–511.
 15. Courtois,G. (2008) Tumor suppressor CYLD: negative regulation of 
NF-kappaB signaling and more. Cell. Mol. Life Sci., 65, 1123–1132.
 16. Wickström,S.A. et al. (2010) CYLD negatively regulates cell-cycle pro-
gression by inactivating HDAC6 and increasing the levels of acetylated 
tubulin. EMBO J., 29, 131–144.
 17. Hellerbrand,C. et al. (2007) Reduced expression of CYLD in human colon 
and hepatocellular carcinomas. Carcinogenesis, 28, 21–27.
 18. Nikolaou,K. et  al. (2012) Inactivation of the deubiquitinase CYLD in 
hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer 
Cell, 21, 738–750.
 19. Font-Burgada,J. et al. (2012) CYLD and HCC: when being too sensitive to 
your dirty neighbors results in self-destruction. Cancer Cell, 21, 711–712.
 20. Chu,L. et al. (2006) Adenoviral vector expressing CYLD augments antitu-
mor activity of TRAIL by suppression of NF-kappaB survival signaling in 
hepatocellular carcinoma. Cancer Biol. Ther., 5, 615–622.
 21. Urbanik,T. et al. (2011) Down-regulation of CYLD as a trigger for NF-κB 
activation and a mechanism of apoptotic resistance in hepatocellular carci-
noma cells. Int. J. Oncol., 38, 121–131.
 22. Gautheron,J. et  al. (2012) A novel player in inflammation and cancer: 
the deubiquitinase CYLD controls HCC development. J. Hepatol., 57, 
937–939.
 23. Bosserhoff,A.K. et al. (2003) Specific expression and regulation of the new 
melanoma inhibitory activity-related gene MIA2 in hepatocytes. J. Biol. 
Chem., 278, 15225–15231.
 24. Amann,T. et  al. (2010) Reduced expression of fibroblast growth fac-
tor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive 
growth. Am. J. Pathol., 176, 1433–1442.
 25. Hellerbrand,C. et al. (2008) The novel gene MIA2 acts as a tumour sup-
pressor in hepatocellular carcinoma. Gut, 57, 243–251.
 26. Sugino,T. et  al. (2008) Sinusoidal tumor angiogenesis is a key compo-
nent in hepatocellular carcinoma metastasis. Clin. Exp. Metastasis, 25, 
835–841.
 27. Sangiovanni,A. et al. (2001) Hepatocyte proliferation and risk of hepatocel-
lular carcinoma in cirrhotic patients. Am. J. Gastroenterol., 96, 1575–1580.
 28. Aderca,I. et al. (2008) The JNK inhibitor SP600129 enhances apoptosis 
of HCC cells induced by the tumor suppressor WWOX. J. Hepatol., 49, 
373–383.
 29. Hashimoto,K. et al. (2004) Analysis of DNA copy number aberrations in 
hepatitis C virus-associated hepatocellular carcinomas by conventional 
CGH and array CGH. Mod. Pathol., 17, 617–622.
 30. Gao,J. et  al. (2008) The tumor suppressor CYLD regulates microtubule 
dynamics and plays a role in cell migration. J. Biol. Chem., 283, 8802–8809.
 31. Miliani de Marval,P. et al. (2011) CYLD inhibits tumorigenesis and metas-
tasis by blocking JNK/AP1 signaling at multiple levels. Cancer Prev. Res. 
(Phila.), 4, 851–859.
 32. Min,L. et  al. (2011) Mitogen-activated protein kinases in hepatocellular 
carcinoma development. Semin. Cancer Biol., 21, 10–20.
 33. Papa,S. et al. (2009) Mechanisms of liver disease: cross-talk between the 
NF-kappaB and JNK pathways. Biol. Chem., 390, 965–976.
 34. Wagner,E.F. et al. (2009) Signal integration by JNK and p38 MAPK path-
ways in cancer development. Nat. Rev. Cancer, 9, 537–549.
 35. Dhanasekaran,D.N. et al. (2008) JNK signaling in apoptosis. Oncogene, 
27, 6245–6251.
 36. Weston,C.R. et  al. (2007) The JNK signal transduction pathway. Curr. 
Opin. Cell Biol., 19, 142–149.
 37. Johnson,G.L. et al. (2007) The c-jun kinase/stress-activated pathway: regu-
lation, function and role in human disease. Biochim. Biophys. Acta, 1773, 
1341–1348.
 38. Hui,L. et  al. (2008) Proliferation of human HCC cells and chemically 
induced mouse liver cancers requires JNK1-dependent p21 downregula-
tion. J. Clin. Invest., 118, 3943–3953.
 39. Sakurai,T. et  al. (2006) Loss of hepatic NF-kappa B activity enhances 
chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 
1 activation. Proc. Natl Acad. Sci. USA, 103, 10544–10551.
 40. Chang,Q. et al. (2009) Sustained JNK1 activation is associated with altered 
histone H3 methylations in human liver cancer. J. Hepatol., 50, 323–333.
 41. Shaulian,E. (2010) AP-1–the Jun proteins: oncogenes or tumor suppressors 
in disguise? Cell. Signal., 22, 894–899.
 42. Lu,X.P. et  al. (1992) Induction of cyclin mRNA and cyclin-associ-
ated histone H1 kinase during liver regeneration. J. Biol. Chem., 267, 
2841–2844.
 43. Zhang,Y.J. et al. (1993) Amplification and overexpression of cyclin D1 in 
human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 196, 
1010–1016.
 44. Brooks,A.R. et al. (1996) Functional analysis of the human cyclin D2 and 
cyclin D3 promoters. J. Biol. Chem., 271, 9090–9099.
 45. Kallunki,T. et al. (1996) c-Jun can recruit JNK to phosphorylate dimeriza-
tion partners via specific docking interactions. Cell, 87, 929–939.
 46. Weiss,C. et  al. (2003) JNK phosphorylation relieves HDAC3-dependent 
suppression of the transcriptional activity of c-Jun. EMBO J., 22, 
3686–3695.
 47. Noguchi,K. et  al. (2001) ASK1-signaling promotes c-Myc protein 
stability during apoptosis. Biochem. Biophys. Res. Commun., 281, 
1313–1320.
 48. Lin,C.P. et  al. (2007) Small-molecule c-Myc inhibitor, 10058-F4, inhib-
its proliferation, downregulates human telomerase reverse transcriptase 
and enhances chemosensitivity in human hepatocellular carcinoma cells. 
Anticancer. Drugs, 18, 161–170.
Received May 14, 2013; revised August 29, 2013; accepted September 7, 
2013
468
Downloaded from https://academic.oup.com/carcin/article-abstract/35/2/461/2462788
by Universitatsbibliothek Regensburg user
on 03 April 2018
